These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 33947317)

  • 1. The non-specific antiviral activity of polysulfates to fight SARS-CoV-2, its mutants and viruses with cationic spikes.
    Vert M
    J Biomater Sci Polym Ed; 2021 Aug; 32(11):1466-1471. PubMed ID: 33947317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyphosphate in Antiviral Protection: A Polyanionic Inorganic Polymer in the Fight Against Coronavirus SARS-CoV-2 Infection.
    Müller WEG; Wang X; Neufurth M; Schröder HC
    Prog Mol Subcell Biol; 2022; 61():145-189. PubMed ID: 35697940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs.
    Witvrouw M; De Clercq E
    Gen Pharmacol; 1997 Oct; 29(4):497-511. PubMed ID: 9352294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-chain polyphosphates impair SARS-CoV-2 infection and replication.
    Ferrucci V; Kong DY; Asadzadeh F; Marrone L; Boccia A; Siciliano R; Criscuolo G; Anastasio C; Quarantelli F; Comegna M; Pisano I; Passariello M; Iacobucci I; Monica RD; Izzo B; Cerino P; Fusco G; Viscardi M; Brandi S; Pierri BM; Borriello G; Tiberio C; Atripaldi L; Bianchi M; Paolella G; Capoluongo E; Castaldo G; Chiariotti L; Monti M; De Lorenzo C; Yun KS; Pascarella S; Cheong JH; Kim HY; Zollo M
    Sci Signal; 2021 Jul; 14(690):. PubMed ID: 34230209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.
    Fröba M; Große M; Setz C; Rauch P; Auth J; Spanaus L; Münch J; Ruetalo N; Schindler M; Morokutti-Kurz M; Graf P; Prieschl-Grassauer E; Grassauer A; Schubert U
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycations and polyanions in SARS-CoV-2 infection.
    Ginsburg I; Fibach E
    Med Hypotheses; 2021 Jan; 146():110470. PubMed ID: 33412501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral Properties of Alginate-Based Biomaterials: Promising Antiviral Agents against SARS-CoV-2.
    Serrano-Aroca Á; Ferrandis-Montesinos M; Wang R
    ACS Appl Bio Mater; 2021 Aug; 4(8):5897-5907. PubMed ID: 35006918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
    Joseph J; Karthika T; Das VRA; Raj VS
    Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
    Müller C; Obermann W; Karl N; Wendel HG; Taroncher-Oldenburg G; Pleschka S; Hartmann RK; Grünweller A; Ziebuhr J
    Antiviral Res; 2021 Feb; 186():105012. PubMed ID: 33422611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
    Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
    J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macromolecular Viral Entry Inhibitors as Broad-Spectrum First-Line Antivirals with Activity against SARS-CoV-2.
    Groß R; Dias Loiola LM; Issmail L; Uhlig N; Eberlein V; Conzelmann C; Olari LR; Rauch L; Lawrenz J; Weil T; Müller JA; Cardoso MB; Gilg A; Larsson O; Höglund U; Pålsson SA; Tvilum AS; Løvschall KB; Kristensen MM; Spetz AL; Hontonnou F; Galloux M; Grunwald T; Zelikin AN; Münch J
    Adv Sci (Weinh); 2022 Jul; 9(20):e2201378. PubMed ID: 35543527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19: Discovery, diagnostics and drug development.
    Asselah T; Durantel D; Pasmant E; Lau G; Schinazi RF
    J Hepatol; 2021 Jan; 74(1):168-184. PubMed ID: 33038433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
    Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion Protein Targeted Antiviral Peptides: Fragment-Based Drug Design (FBDD) Guided Rational Design of Dipeptides Against SARS-CoV-2.
    Manna S; Chowdhury T; Baindara P; Mandal SM
    Curr Protein Pept Sci; 2020; 21(10):938-947. PubMed ID: 32901582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral drug discovery: preparing for the next pandemic.
    Adamson CS; Chibale K; Goss RJM; Jaspars M; Newman DJ; Dorrington RA
    Chem Soc Rev; 2021 Mar; 50(6):3647-3655. PubMed ID: 33524090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Sulfated Glycosaminoglycans Prevent Coronavirus Replication.
    Möller S; Theiß J; Deinert TIL; Golat K; Heinze J; Niemeyer D; Wyrwa R; Schnabelrauch M; Bogner E
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35216006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro.
    Morokutti-Kurz M; Fröba M; Graf P; Große M; Grassauer A; Auth J; Schubert U; Prieschl-Grassauer E
    PLoS One; 2021; 16(2):e0237480. PubMed ID: 33596218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral Effect of Budesonide against SARS-CoV-2.
    Heinen N; Meister TL; Klöhn M; Steinmann E; Todt D; Pfaender S
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?
    Mohammed MEA
    Curr Mol Med; 2022; 22(1):50-66. PubMed ID: 33622224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.